4/1/2022

speaker
Conference Call Operator
Moderator

Greetings and welcome to the BioStage fourth quarter 2021 conference call. At this time, all participants are on a listen-only mode. A question and answer session will follow the formal presentation. If you would like to ask a question, please press star 1 on your telephone keypad. If anyone should require operator assistance during the conference, please press star 0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Peter Pellegrino, Interim Vice President of Finance, Thank you, Sarah. Please go ahead.

speaker
Peter Pellegrino
Interim Vice President of Finance

Good morning. This is Peter Pellegrino, Interim Vice President of Finance. On the call with me today is David Green, our Interim Chief Executive Officer. Before I turn it over to David, let me review the company's forward-looking statements. In our discussion today, we will make statements that constitute forward-looking statements. Our actual results and performance may differ materially. from what we have previously projected due to the risks and uncertainties, including those detailed in our annual report on Form 10-K for the year ended December 31, 2021, and our other public filings. Any forward-looking statements, including those related to our future results and activities, represent our estimates as of today and should not be relied upon us representing our estimates at any subsequent day. Additionally, Any material financial or statistical information presented in the call, which are not included in our press release, will be archived and available in the investor section of our website under events and presentations. Now, I will turn it over to David.

speaker
David Green
Interim Chief Executive Officer

Thank you, Peter, and welcome, everyone. Welcome to this quarterly earnings conference call for BioStage. It has been quite a long time since BioStage has held regular meetings with its shareholders, but this is the start of a new era for BioStage, And from now on, we'll be holding an earnings call every quarter. I was rehired by the board in November last year. And since then, I've already hosted two webinars with investors. I founded BioStage in 2008 at Harvard Bioscience, developed the bioreactor scaffold and cellularization technology, and spun it off as a separate public company in 2013. In 2015, I left BioStage after a nasty road accident that nearly killed me. In November last year, the board asked me to return in order to take Biostage's revolutionary technology to the next level. The share price has almost doubled since I returned. I think it is worth recapping some of the milestone achievements that have got us here. First, we performed the first ever regeneration of an esophagus in a human cancer patient. This was performed by Dr. Dennis Weigel, the chair of thoracic surgery at Mayo Clinic, one of the world's most respected hospitals. Dr. Weigel has been a collaborator with Biostage dating back to the time when I was first CEO. The paper announcing this breakthrough was published in the Journal of Thoracic Oncology Research and Clinical Reports in August 2021. The paper concluded that the biostage esophageal implant, quote, would have considerable clinical use, end quote. In this 75-year-old patient, we saw the regeneration of a functional esophagus with a mucosal lining as well. The mucosal lining is essential to allowing food to slip down to the stomach, and also to act as a barrier to infection. We believe that the patient population that would benefit from a biostage esophageal implant is over 500,000 per year worldwide, and this indication could be worth more than a billion dollars in revenue. Esophageal cancer is one of the most deadly types of cancer. First year survival is only 50%, and five year survival is only 20%. Hence, there's a huge need for better treatment for esophageal cancer. Second, the first in human experience is backed up by the research of the biostage esophageal implant in 45 pigs. This is a very large number of large animal studies, some of which went on for almost two years. This is because the product is novel, and we needed to really understand the science of organ regeneration. Third, one of these implants was not in the esophagus, but instead in the bronchus or airway. This pig showed regeneration of both a bronchial tube and an epithelial lining, which in the airway is just as essential as is the mucosal lining in the esophagus. This pig survived almost two years until scheduled euthanasia. Hence, we already have a second potential indication for use of our technology in the airway. This has the potential to treat a proportion of lung cancer patients where the cancer is confined to the bronchus. We believe this patient population is over 100,000 patients per year worldwide, and this indication could also be worth more than a billion dollars in revenue. Four, the Biostage esophageal implant has been described as revolutionary by Dr. Christine Fink, the surgeon-in-chief at Connecticut Children's Medical Center. CCMC has a long time collaborated with Biostage on the pediatric application of our technology, and CCMC is also an investor in Biostage. It has been described as a breakthrough Quote, unquote, by Dr. J. Vacanti. Dr. J. Vacanti is widely regarded as one of the fathers of the entire field of regenerative medicine, who is now the Emeritus Chair of Pediatric Surgery at Massachusetts General Hospital. We are very proud to have both Drs. Fink and Vacanti on our Scientific Advisory Board, where they have been very helpful in establishing the research agenda for Biostage's next product developments. Five. Based on the work that Dr. Fink did implanting the biostage esophageal implant in 15 piglets, we published another paper in January this year that lays both the scientific and the clinical groundwork for the use of the biostage esophageal implant in babies born with birth defects in the esophagus. Six, the FDA approved our clinical trial for 10 patients in up to five hospitals in the United States. This trial measures both safety and efficacy in the actual patient population. Hence, it is more like a miniature Phase III trial than a typical Phase I safety study in healthy adult volunteers, as is common for small molecule drug development. We expect to add patients to this trial until we have sufficient data to file the Biologic License Application, or BLA, to seek approval to market the biostage esophageal implant in the U.S. This FDA-approved trial allows us to treat babies with birth defects once we have shown safety in adults. In addition, we'll also be seeking to initiate trials in China and the EU, where there are far more patients than there are in the U.S. In addition, both China and the EU allow for conditional approval, which would allow us to market a product and receive revenue after successful Phase II results. This would likely be earlier than is possible in the U.S., which does not have a conditional approval pathway. Seven, BioStage has raised over $22 million in the last four years, mostly from private individuals who have got to know Biostage, its technology and potential, and who are long-term strategic investors. None of these investors is a hedge fund. Our balance sheet is all common stock. There is no preferred stock or convertible debt on our books. One of these investors is me. I invested a quarter of a million dollars in Biostage when I joined in November last year, and apart from the legally required minimum wage, I'm paid entirely in stock options. Hence, Every month, I'm investing in BioStage. My employment is not a drain on the cash flow of the company. All of our employees are also compensated in part through stock options. Eight, we have seven issued patents in the United States and two more in China. These cover the bioreactor, the scaffold, and the retrievable nature of the scaffold, which leaves no permanent implant in the body. We also have two orphan drug designations, one for the trachea, one for the esophagus, which provides seven years of exclusivity in addition to the patents in the US from the date of the approval of the product. So, Buyer Stage has accomplished a lot in the last few years. Despite these successes, Buyer Stage was not able to raise sufficient capital to begin the terms of trial or to get relisted on NASDAQ. Today, we trade on the OTC bulletin board or pink sheets because Buyer Stage was delisted from NASDAQ in 2017. My goals are to raise capital, relist on NASDAQ, and begin the clinical trial. But that is all in the future. So first, let us review the financials for the last year.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-